Carbohydrate antigen 19‐9 plus carcinoembryonic antigen for prognosis in colorectal cancer: An observational study. (27th October 2022)

• Record Type: Journal Article
• Authors: Lee, Jong O.; Kim, Minjung; Lee, Jeong‐Hwan; Kim, Youngmin; Lim, Han‐Ki; Kwon, Yoon‐Hye; Shin, Rumi; Park, Ji W.; Ryoo, Seung‐Bum; Park, Kyu J.; Jeong, Seung‐Yong
• Is Part Of: Colorectal disease. Volume 25:Number 2(2023)
• Page Start: 272
• Page End: 281
• Publication Date: 2022-10-27
• Subjects: Colon (Anatomy) -- Diseases -- Periodicals; Rectum -- Diseases -- Periodicals; 616.34
• DOI: 10.1111/codi.16372
• Languages: English
• ISSNs: 1462-8910

Abstract

Abstract: Aim: Carcinoembryonic antigen (CEA) is a primary prognostic marker and can detect colorectal cancer (CRC) recurrence; however, it has low sensitivity. Carbohydrate antigen 19‐9 (CA 19‐9) can be used as a supplemental tumour marker along with CEA. The purpose of this study was to determine whether preoperative CA 19‐9 added to CEA helped predict long‐term prognosis and whether follow‐up CA 19‐9 added to CEA had additional benefits in diagnosing the recurrence of CRC. Method: We retrospectively assessed patients who underwent surgery for primary CRC between January 2004 and December 2015 at Seoul National University Hospital. Data on demographics, preoperative and follow‐up CEA and CA 19‐9 levels, recurrence and survival were obtained and analysed with respect to tumour marker levels to ascertain their prognostic and diagnostic values. Results: A total of 4972 and 1530 patients were included to analyse preoperative and follow‐up tumour marker levels, respectively. The 5‐year relapse‐free survival rates were 72.2% ± 0.8%, 52.5% ± 2.2%, 55.5% ± 3.2% and 32.1% ± 2.3% in the normal CEA and CA 19‐9, high CEA, high CA 19‐9, and high CEA and high CA 19‐9 groups, respectively (all P < 0.001). Patients whose elevated CEA or CA 19‐9 levels reduced to normal levels had better survival outcomes than those with postoperatively elevated levels. Elevated follow‐up CA 19‐9 and CEA levels were related to higher incidences of distant metastasis (CA 19‐9, 14.0% vs. 23.1%, P = 0.004; CEA, 12.6% vs. 30.1%, P < 0.001) but not to local recurrence. Combined follow‐up CEA and CA 19‐9 increased the sensitivity for recurrence to 31.4%, with a 5% difference from the sensitivity of CEA alone. In the subgroup with high preoperative CA 19‐9 levels, sensitivity increased by 18.2% overall. Conclusion: CA 19‐9 is a valuable prognostic and diagnostic marker for CRC when used adjunctively with CEA and can be a supplementary marker with CEA to improve sensitivity, especially with elevated preoperative CA 19‐9.